White matter hyperintensities (WMH) are areas of increased signal intensity on T2-weighted and fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequences. These lesions represent white matter damage due to various pathological processes, including small vessel disease, demyelination, and axonal loss. WMH are highly prevalent in aging populations and are strongly associated with cognitive decline, gait disturbances, and increased risk of dementia.
The presence and progression of WMH are particularly relevant in neurodegenerative diseases, where they interact with core pathologies like amyloid-beta plaques and tau neurofibrillary tangles to accelerate clinical deterioration. Understanding WMH pathophysiology is essential for developing comprehensive therapeutic approaches that target both vascular and neurodegenerative mechanisms[1].
WMH are primarily detected using the following MRI techniques[2]:
FLAIR (Fluid-Attenuated Inversion Recovery): The gold standard for WMH visualization. FLAIR suppresses cerebrospinal fluid signal, making periventricular and deep white matter lesions more conspicuous. Hyperintense lesions on FLAIR indicate increased water content due to demyelination, axonal loss, or edema[3].
T2-Weighted Imaging: Provides complementary information about lesion age and composition. Acute WMH may show restricted diffusion, while chronic lesions appear as stable hyperintensities.
T1-Weighted Imaging: Helps distinguish WMH from other pathologies. Hypointense lesions on T1 may indicate more severe tissue damage, including cavitation or liquefactive necrosis[4].
WMH burden is commonly quantified using:
The Fazekas scale is the most widely used visual rating system for WMH[9]:
Higher Fazekas scores correlate with increased risk of stroke, dementia, and mortality in elderly populations[10].
Hypertension: The strongest modifiable risk factor for WMH progression. Chronic hypertension leads to arteriosclerosis, lipohyalinosis, and failure of cerebral autoregulation[11].
Diabetes Mellitus: Hyperglycemia promotes endothelial dysfunction, advanced glycation end-product formation, and microvascular rarefaction[12].
Smoking: Accelerates atherosclerosis and promotes pro-inflammatory states that damage cerebral white matter[13].
Age: The most significant non-modifiable risk factor. WMH prevalence increases from approximately 10% in individuals aged 60-70 to over 90% in those over 80[14].
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL): Caused by NOTCH3 mutations, leads to severe WMH, lacunar infarcts, and early-onset dementia[15].
APOE ε4 Allele: Associated with increased WMH burden and faster progression, particularly in Alzheimer's disease[16].
WMH and Alzheimer's disease pathology interact through multiple mechanisms[17]:
Autopsy studies reveal that over 60% of dementia cases have mixed AD-vascular pathology, where WMH significantly contribute to cognitive impairment beyond what would be expected from AD pathology alone[20].
WMH contribute to vascular cognitive impairment through several mechanisms[21]:
White matter lesions disrupt functional connectivity between brain regions. Disconnection of prefrontal circuits underlies executive dysfunction, while parietal-frontal disconnection contributes to attentional deficits[22].
Chronic WMH show activation of microglia, astrocytes, and perivascular macrophages. This neuroinflammatory state promotes progressive white matter damage and neuronal dysfunction in connected cortical regions[20:1].
WMH regions demonstrate impaired cerebral autoregulation and reduced blood flow. This chronic hypoperfusion creates a vicious cycle of energy failure, inflammation, and white matter damage[23].
BBB breakdown is a key contributor to WMH pathogenesis[24]:
Contrast-enhanced MRI and dynamic susceptibility contrast perfusion imaging can detect BBB leakage associated with WMH. Elevated CSF/serum albumin ratio also indicates BBB dysfunction[25].
Enlarged perivascular spaces (EPVS) frequently accompany WMH. These spaces, which normally contain perivascular cerebrospinal fluid flow pathways, become dilated when waste clearance is impaired[26].
Blood Pressure Control: Aggressive BP lowering reduces WMH progression by 20-40% in hypertensive individuals[27].
Statin Therapy: May reduce WMH progression through lipid-lowering and anti-inflammatory effects[28].
Anticoagulation: In CADASIL and other small vessel diseases, careful anticoagulation may prevent new WMH formation[29].
Anti-inflammatory Therapies: Targeting microglial activation may slow WMH progression[30].
Neurorestorative Agents: Growth factors and stem cell approaches aim to promote white matter repair[31].
Glymphatic Enhancement: Improving sleep quality, upright positioning, and aquaporin-4 targeting may enhance waste clearance[32].
Prins & Scheltens, White matter hyperintensities. Nature Reviews Neurology (2015). 2015. ↩︎
Alber et al. MRI of white matter. Neurology (2019). 2019. ↩︎
Bradley et al. FLAIR imaging. Radiographics (2000). 2000. ↩︎
Scheltens et al. White matter lesions on MRI. Brain (1998). 1998. ↩︎
Fazekas et al. MR of white matter lesions. J Neuroradiol (1987). 1987. ↩︎
Wahlund et al. ARWMC scale. Stroke (2001). 2001. ↩︎
Fiske et al. Automated WMH segmentation. Neuroimage (2015). 2015. ↩︎
Nordin et al. DTI in WMH. Neurology (2022). 2022. ↩︎
Fazekas et al. White matter lesions. J Neurol Sci (1993). 1993. ↩︎
van Straaten et al. Fazekas score and outcomes. Stroke (2006). 2006. ↩︎
Pantoni, Cerebral small vessel disease. Lancet Neurology (2010). 2010. ↩︎
van Harten et al. Diabetes and WMH. Diabetes (2007). 2007. ↩︎
Power et al. Smoking and WMH. Stroke (2015). 2015. ↩︎
Launer et al. Epidemiology of WMH. Neurology (2000). 2000. ↩︎
Chabriat et al. CADASIL. Lancet Neurology (2009). 2009. ↩︎
Schott et al. APOE and WMH. Neurology (2006). 2006. ↩︎
Attems & Jellinger, Amyloid and tau. Acta Neuropathol (2014). 2014. ↩︎
Iliff et al. Glymphatic system. J Clin Invest (2013). 2013. ↩︎
Benedictus et al. Tau and WMH. Neurology (2015). 2015. ↩︎
Gouw et al. Inflammation in WMH. Neurology (2011). 2011. ↩︎ ↩︎
Gorelick et al. Vascular cognitive impairment. Stroke (2011). 2011. ↩︎
Duering et al. Disconnection and cognition. Brain (2012). 2012. ↩︎
Marstrand et al. Cerebral blood flow in WMH. Stroke (2005). 2005. ↩︎
Topakian et al. BBB dysfunction in WMH. Ann Neurol (2010). 2010. ↩︎
Starr et al. Albumin ratio and BBB. J Neurol Neurosurg Psychiatry (2003). 2003. ↩︎
Potter et al. Perivascular spaces. Neurobiology of Aging (2015). 2015. ↩︎
Dufouil et al. BP lowering and WMH. Neurology (2005). 2005. ↩︎
Tenorio-Lopes et al. Statins and WMH. J Am Heart Assoc (2022). 2022. ↩︎
Pipes et al. Anticoagulation in CADASIL. Neurology (2021). 2021. ↩︎
Weinstein et al. Anti-inflammatory therapy in WMH. Alzheimer's & Dementia (2023). 2023. ↩︎
Chen et al. White matter repair. Nature Reviews Neurology (2020). 2020. ↩︎
Nedergaard et al. Glymphatic enhancement. Science (2013). 2013. ↩︎